Catalent’s SMARTag® Technology: Differentiated Solutions for Optimal ADC

Time: 11:15 am
day: Track B - Day 1 - AM


• Demonstrating how SMARTag is a clinicalstage ADC technology featuring sitespecific conjugation with multiple linker and warhead options
• 6 CRs and 2 PRs among 22 patients were achieved by TRPH-222, a CD22-targeted SMARTag conjugate, in the dose-escalation stage of a Phase 1 trial for R/R B-cell lymphoma
• Highlighting how new linkers are being used to achieve proprietary high DAR ADCs featuring topoisomerase I inhibitor payloads
• Showcasing how conjugate stability has been demonstrated —even with cleavable linkers—to deliver efficacy with improved tolerability and a wider therapeutic window